The performance of companies tied to Sildenafil's past presents a challenging investment picture . While the initial success generated substantial profits , generic alternatives have significantly impacted sales . Investing in connected pharmaceutical companies now requires a thorough assessment of proprietary safeguards, evolving healthcare shifts